An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment



Status:Recruiting
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/2/2019
Start Date:March 13, 2018
End Date:April 16, 2022
Contact:Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
Email:Clinical.Trials@bms.com
Phone:please email:

Use our guide to learn which trials are right for you!

ADaptiVe Biomarker Trial That InformS Evolution of Therapy

The purpose of this study is to evaluate the treatment of solid tumors with various
immunotherapy combinations. The treatment will be determined based upon a broad biomarker
assessment.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Participants must have an ECOG performance status of less than or equal to 1

- Participants must have had prior therapy

- Participants must have at least 2 lesions with measurable disease as defined by RECIST
Version 1.1

Exclusion Criteria:

- Participants must not have suspected, known, or progressive CNS metastases, have
untreated CNS metastases, or have the CNS as the only site of disease

- Participants must not have carcinomatous meningitis

- Participants must not have other active malignancy requiring concurrent intervention

Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
3
sites
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Baltimore, Maryland 21237
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Chicago, Illinois 60637
?
mi
from
Chicago, IL
Click here to add this to my saved trials